Dermatophytic Onychomycosis Therapeutics Market is segmented By Product Type (Nail Paints, Tablets), By Treatment Type (Topical Mode, Oral Mode of Treatment), By Distribution Channel (Retail pharmacies, Online Channels, Hospitals & Clinics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Dermatophytic Onychomycosis Therapeutics Market Overview
The Dermatophytic Onychomycosis Therapeutics Market is estimated to reach at a high CAGR 6.4% during the forecast period 2023-2030.
Dermatophytic onychomycosis is ringworm of the nail. It is the most common fungus infection of the nails (onychomycosis). Onychomycosis makes the nails look white and opaque, thickened, and brittle.
Dermatophytic Onychomycosis Therapeutics Market Scope
|
Metrics |
Details |
|
Market CAGR |
6.4% |
|
Segments Covered |
By Product Type, By Treatment Type, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Know More Download Sample
Dermatophytic Onychomycosis Therapeutics Market Dynamics
The increasing prevalence of nail fungus and increasing awareness of dermatophytic onychomycosis therapeutics among podiatrists and dermatologists will increase its market.
The increasing prevalence of nail fungus will increase the dermatophytic onychomycosis therapeutics (DOT) Market in the forecast period
Majority of fungal superficial infections are caused by dermatophytes, which belong to three genera (Epidermophyton, Microsporum and Trichophyton) with T. rubrum being the most prominent cause of nail infection. The prevalence rate of onychomycosis has been reported to be as high as 23% across Europe and 20% in East Asia. In North America, the incidence of onychomycosis is up to 14%, with fungal infection responsible for 50% of all nail diseases. With annually millions of dollars being spent on oral and topical prescriptions, laser treatments, home remedies and over-the-counter products, it is obvious that people are still bothered by their fungal toenail infections and are determined to get rid of them. Dermatophytes invade the nail plate in fungal nail infection. The infection increases with age. Several studies report a prevalence of 15-20% in patients aged ≥40 years. In the general population, the prevalence is 3-5%.
Increasing awareness of dermatophytic onychomycosis therapeutics among podiatrists and dermatologists will increase its market
Due to the ease of detection by use of the internet the diagnosis and treatment of onychomycosis have entered a new era which in some ways is trivial. Patients can detect diagnosis before it has been clinically proven. Still clinicians are encouraged to use topical therapies, which were once thought to be ineffective, now have been proven more safe and effective in clinical trials. As the mechanisms of therapy have become more easy, so has the success rate, which encourages both patients and practitioners to adhere to therapy despite the time needed to achieve the clearance of disease. Moreover, as the mechanisms of therapy are better consolidated and understood into potential regimens, there will be more clinical experience and study data necessary to understand the utility of combinations between systemic treatments and topical therapies. In addition to concomitant use of nail polish, topical keratolytics and the optimization in patients with diabetes mellitus, peripheral vascular diseases, and other comorbidities.
The negligence towards this infection and treatment failure will hamper the dermatophytic onychomycosis therapeutics (DOT) market
Although terbinafine is demonstrably the most effective agent in dermatophyte onychomycosis a consistent failure rate of 20–30% is found in all studies. Incase, the most obvious causes of treatment failure,poor absorption, notably poor compliance, immunosuppression, zero nail growth and dermatophyte resistance, are excluded, the commonest cause of failure is likely to be kinetic. Subungual dermatophytoma has been described and it is expected that this tightly packed mass of fungus prevents drug penetration in adequate concentrations. In such cases, partial nail removal is indicated. It has been demonstrated that close to 100% cure rates can always be achieved if all affected nails are avulsed under ring block before the commencement of treatment. Many risk factors have been identified for onychomycosis. They include peripheral vascular disease, hyperhidrosis and increasing age trauma. Fungal nail disease is more prevalent in men and individuals with nail problems such as psoriasis, in persons with immunosuppressive conditions such as HIV infection or diabetes mellitus, and those taking immunosuppressive medications. Pharmacological gold standard treatments for onychomycosis have been associated with increasing antifungal resistance and low success rates suggesting that treatment outcome is dependent on multiple variables.
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and adverse health from the COVID-19 pandemic. This has seen to affect the dermatophytic onychomycosis therapeutics (DOT) as many pharmaceutical industries have stopped manufacturing units.
Dermatophytic Onychomycosis Therapeutics (DOT) Market Segment Analysis
Nail Paints segment will dominate the dermatophytic onychomycosis therapeutics (DOT) market
Trichophyton rubrum a fungus, causes painful infection of the fingernails and toe. Prevalent in wet work zones and coastal regions, the infection is known as Onychomycosis accounts for about half of all nail diseases. It causes brittleness, discoloration, and disfigurement of nails. The disease needs prolonged treatment with both ointments and oral medication, which
have side effects and are expensive. Delhi-based researchers from Hamdard Institute of Medical Sciences and Research have developed a novel translucent nail lacquer fortified with an antifungal drug to treat onychomycosis. The drug-infused, quick-drying polymer can be easily applied like nail polish. This nail lacquer has shown promising results in delivering the antifungal drug for extended durations indicating its potential use as a topical application and effective remedy to treat onychomycosis.
The antifungal Bilayer Nail Lacquer (BNL) reduces the need for frequent drug application, improves the cosmetic appearance and yields therapeutic fruitful outcomes. It helps to overcome problems associated with conventional formulations and offers a novel drug delivery platform for the successful treatment of onychomycosis The researchers used readily available and approved antifungal drug Luliconazole and incorporated it into the polymer matrix. The drug is mixed with an organic solvent by using a magnetic stirrer. To this solution, film-forming polymers, plasticizers, humectants, and permeation enhancers were added sequentially to obtain the polymer. The drug-laden, water-compatible polymer was obtained after evaporating the solvent.
Topical mode dominated the dermatophytic onychomycosis therapeutics (DOT) market
Superficial white onychomycosis and distal lateral subungual onychomycosis limited to the distal nail can be treated with a topical agent. The combination of topical and systemic treatment increases the cure rate. Topical antifungals are an important adjuvant in the treatment of dermatophytosis. Also, specific situations such as dermatophytoses in pregnancy and infants often warrant topical therapy. Several new topical antifungals and newer formulations promise enhanced effectiveness of topical therapy in dermatophytosis. The advantages of topical antifungal therapy over oral antifungals include lack of systemic side effects and complications due to limited systemic absorption, very low incidence of drug interactions, ease of use, comparatively low cost of therapy, and an additional benefit of anti-inflammatory activity of several topical antifungals including azoles and allylamines.
There currently are three topical agents approved by the US Food and Drug Administration (FDA) to treat onychomycosis: tavaborole, efinaconazole, and ciclopirox. The U.S FDA recently approved a supplemental New Drug Application for efinaconazole (JUBLIA) topical solution, 10%, to treat onychomycosis.
The retail pharmacies segment will dominate the dermatophytic onychomycosis therapeutics (DOT) market
Although several treatments are available for onychomycosis, poor treatment adherence (<25%) and long treatment durations often result in poor outcomes such as relapse and reinfection.5,6 Pharmacy technicians can improve onychomycosis outcomes by referring patients to the pharmacist for treatment selection and educating patients on treatment expectations. Technicians can also reinforce treatment adherence when patients come to the pharmacy for medication refills.
Numerous over-the-counter (OTC) medications and products are available to prevent or stop the growth of toenail fungus. Products like OTC Lotrimin AF (containing the antifungal clotrimazole), Scholl Fungal Nail Treatment, and OTC Lamisil (containing the antifungal terbinafine) can be purchased without a prescription. Owing to the increasing sales of OTC drugs, this segment will see an increase in its market.
Dermatophytic Onychomycosis Therapeutics Market Geographical Share
North America region will dominate the dermatophytic onychomycosis therapeutics (dot) market
The rising research and development, an increasing number of prescriptions for onychomycosis, and demand for jublia and kerydin will dominate the market in this region.
On December 9, 2019, Moberg Pharma AB has announced that MOB-015 (topical terbinafine) met the primary endpoint as well as the secondary endpoints in the North American Phase 3 study, including patients with mild to moderate toenail onychomycosis. The purpose of this multicenter, randomized , controlled clinical Phase 3 study was to evaluate the safety and efficacy of MOB-015 in patients with mild to moderate distal subungual onychomycosis (DSO) affecting 20-60 % of the great toenail. The study was conducted at 32 sites in Canada and the U.S. with 365 patients, 246 patients receiving MOB-015, and 119 patients receiving vehicles. Patients received treatment during 48 weeks and had the last follow-up assessment at week 52.
Lupin received approval to launch Tavaborole Topical Solution, 5 percent in United States (US) from the United States Food and Drug Administration (FDA).
Dermatophytic Onychomycosis Therapeutics Market Companies
Major key players in the dermatophytic onychomycosis therapeutics (DOT) market are Kaken Pharmaceutical, Valeant Pharmaceuticals Inc., Galderma S.A., Trumac Healthcare Ltd, Pfizer, Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Medimetriks Pharmaceuticals, Inc
Dermatophytic Onychomycosis Therapeutics (DOT) Market Key Companies to Watch
Kaken Pharmaceutical Co., Ltd
Overview: A specialty pharmaceutical company in Japan, Kaken Pharmaceutical Co., Ltd. (KAKEN) with strong experience in commercializing and developing novel pharmaceuticals and medical devices in orthopedics and dermatology.
Product Portfolio: The company comprises business activities that include the production and marketing of pharmaceuticals such as streptomycin, an anti-tuberculosis drug, and various antifungal agents. In recent years, KAKEN concentrates its R&D resources on the immune system, the nervous system, and infectious diseases.
Key Development: On March 2, 2020-Kaken Pharmaceutical Co., Ltd. has announced that Kaken’s licensing partner, Main Life Corp., Ltd., has launched Jublia, a topical formulation drug for Onychomycosis (generic name: efinaconazole; product name in Japan: Clenafin®) in Hong Kong.
The Dermatophytic Onychomycosis Therapeutics (DOT) Market report would provide an access to an approx. 60 market data table, 49 figures and 200 pages.
